MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8 EUR | -0.50% |
|
-.--% | +14.61% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4M 4.34M 341M | Sales 2025 * | 4.4M 4.78M 375M | Capitalization | 111M 121M 9.47B |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -31.47M -2.47B | Net income 2025 * | -29M -31.47M -2.47B | EV / Sales 2024 * | 25.6 x |
| Net cash position 2024 * | 8.6M 9.33M 733M | Net cash position 2025 * | 7.9M 8.57M 673M | EV / Sales 2025 * | 23.5 x |
| P/E ratio 2024 * |
-3.43
x | P/E ratio 2025 * |
-3.35
x | Employees | 56 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on MaaT Pharma
More press releases
| 1 day | -0.50% | ||
| 1 month | -13.23% | ||
| 3 months | +0.76% | ||
| 6 months | +23.08% | ||
| Current year | +14.61% |
1 week
7.94
8.18
1 month
7.849.58
Current year
6.409.90
1 year
4.509.90
3 years
4.5014.40
5 years
4.5014.40
10 years
4.5014.40
| Managers | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
FOU | Founder | - | 31/12/13 |
Siân Crouzet
DFI | Director of Finance/CFO | - | 31/12/15 |
| Chief Tech/Sci/R&D Officer | - | 28/02/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 31/12/13 | |
Claude Bertrand
BRD | Director/Board Member | 62 | 15/07/20 |
Muriel Prudent
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 8 | -0.50% | 808 |
| 30/05/24 | 8.04 | +0.50% | 1,001 |
| 29/05/24 | 8 | -.--% | 771 |
| 28/05/24 | 8 | -.--% | 1,529 |
| 27/05/24 | 8 | -.--% | 314 |
Real-time Euronext Paris, May 31, 2024 at 02:24 pm
More quotes
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
10/06/2024
- Portzamparc Mid & Small Caps Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8
EUR
Average target price
14.6
EUR
Spread / Average Target
+82.50%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.61% | 121M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- MAAT Stock
